Edelman’s research interests combine his scientific and medical training. His work integrates multiple disciplines including polymer based controlled and modulated drug delivery; growth factor biology and biochemistry; tissue engineering; biomaterials-tissue interactions and the vascular response to injury. He uses elements of continuum mechanics, digital signal processing and polymeric controlled release technology to examine the cellular and molecular mechanisms that produce accelerated atherosclerosis and transform stable coronary artery disease to unstable coronary syndromes. With this as a foundation the Edelman laboratory set the way for the development and optimization of most of the clinically approved bare metal and drug-eluting endovascular stents. His work on angiogenesis includes basic studies of endothelial cell and vascular biology, computational modeling of vessel formation, and creation and use of controlled angiogenic factor release devices in clinical trials. His most recent publications have focused on how tissue engineered cells might be used for the local delivery of growth factors and growth inhibitors in the study of the vascular homeostasis and repair, cancer invasiveness and metastases and the homology between endothelial paracrine and angiocrine regulation in cancer and vascular diseases. He has mentored more than 100 graduate students and postdoctoral fellows.
Edelman has spent significant time on public health policy. As chief scientific adviser of the journal Science: Translational Medicine he has set the tone for the national debate on the future of translational research and innovation. As co-founder and chair of ASTM F04.03 that creates the standards for cardiovascular implants he outlined many of the guidance documents and white papers that set regulatory recommendations. He is a member of FDA’s Science Advisory Board, an external reviewer of CDRH and an ORISE fellow in the EIR program at the FDA.
Edelman received his prize and presented his work at Columbia University Oct. 27.